Pharmaceuticals News and Research

RSS

Nine thousand patients to take part in Nowegian study on opening of narrowed coronary arteries

Nine thousand patients will take part in a clinical trial to determine the best method of opening narrowed coronary arteries. The results of the study may lead to substantial cost savings - and save lives.

9 Feb 2011

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it has received a Notice of Non-Compliance (NON) from Health Canada regarding its New Drug Submission (NDS) for Feraheme® (ferumoxytol) injection for intravenous (IV) use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.

9 Feb 2011

FDA grants Actavis marketing approval for Pantoprazole Sodium Delayed-Release Tablets

Actavis Group, an international generic pharmaceuticals company, today announced that it has received approval from the US Food & Drug Administration to market Pantoprazole Sodium Delayed-Release Tablets, USP.

9 Feb 2011

CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that results from a series of preclinical studies show that bafetinib may be useful in preventing bone loss in cancer patients who are at high risk for this event.

8 Feb 2011

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.

8 Feb 2011

Anti-cancer shots for boys in the pipeline

The Pharmaceutical Benefits Advisory Committee (PBAC) is deciding on whether to include the human papillomavirus (HPV) vaccine, Gardasil in in the National Immunization Program for boys.

8 Feb 2011

Avandia label revised as per FDA directive

Following the 2010 FDA directive, pharmaceutical manufacturer Glaxo-SmithKline announced this Monday that they have modified the label for diabetes drug rosiglitazone (Avandia). The new label restricts its use to patients already taking it or to those who have failed other antiglycemic drugs.

8 Feb 2011

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

ScinoPharm, a leading active pharmaceutical ingredient (API) and contract research and manufacturing (CRAM) service provider to the global pharmaceutical and biotechnology industry, will provide commercial manufacturing service of vilazodone hydrochloride active pharmaceutical ingredient (API) for Clinical Data, Inc.'s Viibryd™, a new drug entity recently approved by the United States Food and Drug Administration.

8 Feb 2011

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Ansaris announced today that it has received a milestone payment for the successful identification of a kinase-related compound under its drug discovery collaboration with Ono Pharmaceutical Co., Ltd. Ono will initiate the preclinical study of the identified compound. This collaboration between Ansaris and Ono was established to focus on the discovery of kinase-related compounds for the treatment of cancer, inflammatory and autoimmune diseases.

8 Feb 2011

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan Corporation, plc today reported its fourth quarter and full-year 2010 financial results and provided financial guidance for 2011.

8 Feb 2011

NKT, DSM sign contract to develop therapeutics based on natural killer T cells

DSM Biologics, a business unit of DSM Pharmaceutical Products, today announced the signing of a contract with NKT Therapeutics, Inc. based in Waltham, Mass, USA, the biotechnology company that focuses on developing therapeutics based on unique immune cells called natural killer T cells.

8 Feb 2011

Teva fourth quarter net sales increase 16% to record $4.4 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2010.

8 Feb 2011

Almac opens analytical facility at new 240,000 sq. ft. North American Headquarters

Almac's new 240,000 sq. ft. North American Headquarters, built on 40 acres in Souderton, PA, north of Philadelphia is part of the Almac Group's integrated services solutions strategy. The new facility delivers full-service, integrated clinical packaging, drug supply management and technology solutions to pharmaceutical and biotech clients.

8 Feb 2011

TREK1 activity offers a key target for fluoxetine and other antidepressant drugs

Using a unique and relatively simple cell-based fluorescent assay they developed, scientists with the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the University of California, Berkeley have identified a means by which fluoxetine, the active ingredient in Prozac, suppresses the activity of the TREK1 potassium channel.

8 Feb 2011

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition Therapeutics Inc., a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the quarter ended December 31, 2010.

8 Feb 2011

Particle Sciences announces strategic alliance with HORIBA Instruments

Particle Sciences, Inc., a leading pharmaceutical CRO, is pleased to announce the establishment of a strategic alliance with HORIBA Instruments of Irvine, CA, which is the U.S. sales and marketing division of HORIBA Limited of Kyoto, Japan.

8 Feb 2011

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Tufts University today announced the public launch of the Tufts Institute for Biomedical Partnerships website/HUB: www.tuftspharmapartners.org.

8 Feb 2011

Zeria obtains Japanese regulatory clearance for HemCon products

HemCon Medical Technologies, Inc. is pleased to announce that its partner in Japan, Zeria Pharmaceutical Co., Ltd., has obtained regulatory clearance from the Ministry of Health Labor and Welfare for the HemCon® Bandage, GuardaCare™ and ChitoGauze™ product lines and will begin sales through Zeria's subsidiary, Zeria Shoji Co., Ltd.

7 Feb 2011

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Harbor BioSciences, Inc., a biopharmaceutical company developing novel therapeutics for the treatment of cancer, metabolic and inflammatory diseases, today announced it is closing the clinical sites of its U.S.-based Phase I/IIa clinical trial with Apoptone® (HE3235) for castration resistant prostate cancer (CRPC) – also referred to as hormone resistant prostate cancer.

7 Feb 2011

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Progenics Pharmaceuticals, Inc. and Salix Pharmaceuticals, Ltd. today announced that they have entered into an exclusive worldwide (except Japan) agreement by which Salix has licensed rights to RELISTOR® (methylnaltrexone bromide).

7 Feb 2011

Pharmaceuticals News and Research

Nine thousand patients to take part in Nowegian study on opening of narrowed coronary arteries

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

FDA grants Actavis marketing approval for Pantoprazole Sodium Delayed-Release Tablets

CytRx's bafetinib helps reduce skeletal complications in cancer patients

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Anti-cancer shots for boys in the pipeline

Avandia label revised as per FDA directive

ScinoPharm to be Clinical Data's sole API supplier of vilazodone hydrochloride during Viibryd's launch

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Elan 2010 total revenue increases 5% to $1,169.7 million

NKT, DSM sign contract to develop therapeutics based on natural killer T cells

Teva fourth quarter net sales increase 16% to record $4.4 billion

Almac opens analytical facility at new 240,000 sq. ft. North American Headquarters

TREK1 activity offers a key target for fluoxetine and other antidepressant drugs

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Particle Sciences announces strategic alliance with HORIBA Instruments

Tufts announces public launch of Institute for Biomedical Partnerships, HUB website

Zeria obtains Japanese regulatory clearance for HemCon products

Harbor BioSciences closes U.S.-based Apoptone Phase I/IIa clinical trial for castration resistant prostate cancer

Progenics, Salix enter exclusive worldwide license agreement for RELISTOR

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence